Added to YB: 2026-06-30
Pitch date: 2026-06-26
NVO [bullish]
Novo Nordisk A/S
-17.95%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 47.29
Price Target
N/A
Dividend
4.62%
EV/EBITDA
6.92
P/E
9.66
EV/Sales
3.69
Sector
Pharmaceuticals
Category
turnaround
5 Great Businesses with Broken Stock Prices - Novo Nordisk A/S
NVO: GLP-1 leader down over the last year on disappointing Q4, but new mgmt likely sandbagged guidance after prior team overpromised. Expectations reset post-Lilly competition fears. Early oral Wegovy scripts strongly outperforming Lilly's Orforglipron & Zepbound launch. Guidance raise + re-rating likely if momentum holds.
Read full article (1 min)